Filtros de búsqueda

Lista de obras de

AXL is an oncotarget in human colorectal cancer.

artículo científico publicado en 2015

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models

scientific article published on 08 March 2018

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

artículo científico publicado en 2017

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

artículo científico publicado en 2016

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.

artículo científico publicado en 2016

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience

scientific article published on 08 October 2019

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

artículo científico publicado en 2016

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

artículo científico publicado en 2017

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme.

artículo científico publicado en 2017

Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.

artículo científico publicado en 2018

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

scientific article published on 01 March 2019

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer

scientific article published on 16 August 2019

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents

scientific article published on 20 June 2019

Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy

scientific article published on 04 May 2019

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer

scientific article published on 31 July 2019

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

artículo científico publicado en 2020

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models

artículo científico publicado en 2015

Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer

artículo científico publicado en 2016

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets

artículo científico publicado en 2017

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.

artículo científico publicado en 2017

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

artículo científico publicado en 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda